491 related articles for article (PubMed ID: 36051336)
1. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.
Bellanti F; Lo Buglio A; Dobrakowski M; Kasperczyk A; Kasperczyk S; Aich P; Singh SP; Serviddio G; Vendemiale G
World J Gastroenterol; 2022 Jul; 28(26):3243-3257. PubMed ID: 36051336
[TBL] [Abstract][Full Text] [Related]
2. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
[TBL] [Abstract][Full Text] [Related]
3. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.
Bica IC; Stoica RA; Salmen T; Janež A; Volčanšek Š; Popovic D; Muzurovic E; Rizzo M; Stoian AP
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374340
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes.
Ogawa Y; Nakahara T; Ando Y; Yamaoka K; Fujii Y; Uchikawa S; Fujino H; Ono A; Murakami E; Kawaoka T; Miki D; Yamauchi M; Tsuge M; Imamura M; Oka S
Eur J Gastroenterol Hepatol; 2023 Sep; 35(9):989-996. PubMed ID: 37395206
[TBL] [Abstract][Full Text] [Related]
6. Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Hameed I; Hayat J; Marsia S; Samad SA; Khan R; Siddiqui OM; Khan MO; Malik S; Fatima K; Fudim M; Krasuski RA
Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102111. PubMed ID: 36931466
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications.
Scheen AJ
Diabetes Metab; 2019 Jun; 45(3):213-223. PubMed ID: 30708071
[TBL] [Abstract][Full Text] [Related]
8. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
Chrysavgis L; Papatheodoridi AM; Chatzigeorgiou A; Cholongitas E
J Gastroenterol Hepatol; 2021 Apr; 36(4):893-909. PubMed ID: 33439540
[TBL] [Abstract][Full Text] [Related]
9. Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Kuchay MS; Farooqui KJ; Mishra SK; Mithal A
Adv Exp Med Biol; 2021; 1307():213-230. PubMed ID: 32006266
[TBL] [Abstract][Full Text] [Related]
10. Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus.
Shinozaki S; Tahara T; Lefor AK; Ogura M
J Med Invest; 2020; 67(3.4):280-284. PubMed ID: 33148902
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes.
Bajaj HS; Brown RE; Bhullar L; Sohi N; Kalra S; Aronson R
Diabetes Metab; 2018 Dec; 44(6):493-499. PubMed ID: 30149145
[TBL] [Abstract][Full Text] [Related]
12. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Xing B; Zhao Y; Dong B; Zhou Y; Lv W; Zhao W
J Diabetes Investig; 2020 Sep; 11(5):1238-1247. PubMed ID: 32083798
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.
Mirarchi L; Amodeo S; Citarrella R; Licata A; Soresi M; Giannitrapani L
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409028
[TBL] [Abstract][Full Text] [Related]
14. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
15. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Zafar Y; Rashid AM; Siddiqi AK; Ellahi A; Ahmed A; Hussain HU; Ahmed F; Menezes RG; Siddiqi TJ; Maniya MT
Clin Res Hepatol Gastroenterol; 2022; 46(7):101970. PubMed ID: 35659603
[TBL] [Abstract][Full Text] [Related]
16. Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors.
Lombardi R; Mantovani A; Cespiati A; Francione P; Maffi G; Del Zanna E; Maffeis C; Colecchia A; Passigato N; Ferrarese A; Cusumanu CD; Villani R; Orsi E; Grancini V; Airaghi L; Bignamini D; Serviddio G; Targher G; Dongiovanni P; Fargion S; Fracanzani AL
Dig Liver Dis; 2024 Apr; 56(4):551-558. PubMed ID: 37845152
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
Dig Dis Sci; 2020 Feb; 65(2):623-631. PubMed ID: 30684076
[TBL] [Abstract][Full Text] [Related]
18. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Euh W; Lim S; Kim JW
Front Endocrinol (Lausanne); 2021; 12():613389. PubMed ID: 34177796
[TBL] [Abstract][Full Text] [Related]
19. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials.
Coelho FDS; Borges-Canha M; von Hafe M; Neves JS; Vale C; Leite AR; Carvalho D; Leite-Moreira A
Diabetes Metab Res Rev; 2021 Sep; 37(6):e3413. PubMed ID: 33010191
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
Yabiku K
Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
